Precision BioSciences/$DTIL
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Precision BioSciences
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
Ticker
$DTIL
Sector
Primary listing
Employees
102
Headquarters
Website
DTIL Metrics
BasicAdvanced
$56M
-
-$8.78
1.52
-
Price and volume
Market cap
$56M
Beta
1.52
52-week high
$11.08
52-week low
$3.61
Average daily volume
166K
Financial strength
Current ratio
5.178
Quick ratio
4.587
Long term debt to equity
82.322
Total debt to equity
86.466
Interest coverage (TTM)
-66.26%
Profitability
EBITDA (TTM)
-88.168
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-6,205.79%
Operating margin (TTM)
-7,145.92%
Revenue per employee (TTM)
$10,000
Management effectiveness
Return on assets (TTM)
-41.00%
Return on equity (TTM)
-143.89%
Valuation
Price to revenue (TTM)
33.504
Price to book
1.62
Price to tangible book (TTM)
1.65
Price to free cash flow (TTM)
-0.656
Free cash flow yield (TTM)
-152.46%
Free cash flow per share (TTM)
-7.226
Growth
Revenue change (TTM)
-98.56%
Earnings per share change (TTM)
-358.78%
3-year revenue growth (CAGR)
-67.73%
3-year earnings per share growth (CAGR)
-41.84%
What the Analysts think about DTIL
Analyst ratings (Buy, Hold, Sell) for Precision BioSciences stock.
DTIL Financial Performance
Revenues and expenses
DTIL Earnings Performance
Company profitability
DTIL News
AllArticlesVideos
Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update
Business Wire·2 weeks ago
Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B
Business Wire·2 weeks ago
Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025
Business Wire·3 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Precision BioSciences stock?
Precision BioSciences (DTIL) has a market cap of $56M as of August 23, 2025.
What is the P/E ratio for Precision BioSciences stock?
The price to earnings (P/E) ratio for Precision BioSciences (DTIL) stock is 0 as of August 23, 2025.
Does Precision BioSciences stock pay dividends?
No, Precision BioSciences (DTIL) stock does not pay dividends to its shareholders as of August 23, 2025.
When is the next Precision BioSciences dividend payment date?
Precision BioSciences (DTIL) stock does not pay dividends to its shareholders.
What is the beta indicator for Precision BioSciences?
Precision BioSciences (DTIL) has a beta rating of 1.52. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.